An Open Label Phase I Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Vinorelbine in Elderly Patients With Advanced Non Small Lung Cell Cancer - Stage IV
Phase of Trial: Phase I
Latest Information Update: 28 Jan 2016
Price : $35 *
At a glance
- Drugs Nintedanib (Primary) ; Vinorelbine
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms VENUS-1
- 15 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 28 Jun 2013 Actual end date (Jun 2013) added as reported by ClinicalTrials.gov.
- 11 Jun 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.